The Russian Enteromix cancer vaccine is now ready for clinical use, the Russian Federal Medical and Biological Agency (FMBA) has announced.
FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating its safety and high effectiveness.
The vaccine showed significant results in shrinking tumors and slowing their growth, and has also been found safe for repeated use.
The vaccine will be customized for each patient, tailored to their individual RNA, Skvortsova said.
She added that the first form of the vaccine will be used to treat colorectal cancer, while another version is in development for glioblastoma — a brain cancer — and specific types of melanoma, a skin cancer. (Sputnik News)